Chris is a co-leader of the business development transactions capability at Amgen, with a particular focus on the oncology therapeutic area. Chris joined Amgen as part of the Onyx acquisition in October 2013 and is based in San Francisco. Since joining Amgen, he has led a range of transactions including Amgen’s immuno-oncology collaborations with Molecular Partners, CytomX and Kite Pharma. While at Onyx, Chris served as a co-leader of the team responsible for Onyx’s business development strategy and execution and supported Onyx’s sale process. Prior to joining Onyx, Chris was a director in Pfizer’s business development team in New York where supported deals across a broad spectrum of therapeutic areas and geographies. Earlier in his career, Chris worked as a senior consultant in CSC’s healthcare practice.
Chris earned his MBA from NYU’s Stern School of Business, and his BSE in Biomedical Engineering from The Johns Hopkins University.